Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model

Preclinical Pharmacokinetic/Pharmacodynamic Models to Predict Schedule-Dependent Interaction Between Erlotinib and Gemcitabine

(2013) Mengyao Li et al.   PHARMACEUTICAL RESEARCH

pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma

(2012) Gabriella Aquino et al.   CANCER BIOLOGY & THERAPY

Predicting Plasma Concentration of Risperidone Associated With Dosage Change

(2012) Hiroyuki Uchida et al.   THERAPEUTIC DRUG MONITORING

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available Heat Shock Protein 90 Inhibitor in a Human Tumor Xenograft Mouse Model

(2011) S. Yamazaki et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human

(2011) Laurent Salphati et al.   XENOBIOTICA

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

(2009) L. Lee et al.   CLINICAL CANCER RESEARCH

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

(2009) Fabienne Thomas et al.   EUROPEAN JOURNAL OF CANCER

Modeling of tumor growth and anticancer effects of combination therapy

(2009) Gilbert Koch et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models

(2008) S. Yamazaki et al.   DRUG METABOLISM AND DISPOSITION